Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 17/20 | 0.52 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.48 |
| ▸ | KDM5C | P41229 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4117275 | 0.93 | KDM5A (0.49) | KDM5AALDH1A1 | |
| SCHEMBL3756652 | 0.81 | MAPK1 (0.53) | ALDH1A1 | |
| SCHEMBL28586012 | 0.81 | MAPK1 (0.53) | ALDH1A1 | |
| SCHEMBL4270527 | 0.81 | MAPK1 (0.53) | ALDH1A1 | |
| SCHEMBL16992397 | 0.81 | MAPK1 (0.55) | ALDH1A1 | |
| SCHEMBL13853847 | 0.81 | KDM5A (0.51) | KDM5AKDM5BKDM5CKDM4CALDH1A1 | |
| SCHEMBL23142562 | 0.79 | CA1 (0.53) | KDM5A | |
| SCHEMBL3458723 | 0.79 | CA1 (0.53) | KDM5A | |
| SCHEMBL3457791 | 0.79 | CA1 (0.53) | KDM5A | |
| SCHEMBL14167734 | 0.79 | LTA4H (0.39) | KDM5AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716477-A | 7-substituted phosphoryl quinazoline derivative and preparation method and application thereof | 武汉人福创新药物研发中心有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-10022354-B2 | Pyrrolidine amide compounds as histone demethylase inhibitors | GENENTECH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170312252-A1 | PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-3204379-A1 | PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | Genentech, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057924-A1 | PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | GENENTECH, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-8283354-B2 | Voltage gated sodium and calcium channel inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-09 | — | — | US | disclosed |
| US-7928107-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-12-17 | — | — | US | disclosed |
| EP-1784393-B1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1858846-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2007-11-28 | — | — | EP | disclosed |
| EP-1784393-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006097175-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| WO-2006028904-A9 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006028904-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | KDM5A 2146/4885KDM5B 2337/4885KDM5C 1919/4885 |
| US-20170312252-A1 | PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | KDM5A, KDM5C, KDM5B | KDM5A 1/4885KDM5B 3/4885KDM5C 2/4885 |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | KDM5A 2146/4885KDM5B 2337/4885KDM5C 1919/4885 |
| US-10022354-B2 | Pyrrolidine amide compounds as histone demethylase inhibitors | KDM5A, KDM5C, KDM1B | KDM5A 1/4885KDM5B 4/4885KDM5C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.